Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phosphodiesterase enzyme family comprises key regulators of cell signaling via degradation of cyclic nucleotides. These enzymes catalyze the hydrolysis of phosphodiester bonds in cAMP and cGMP, thereby controlling the amplitude and duration of signaling pathways. The superfamily consists of 11 families (PDE1-PDE11), each with distinct substrate specificities, regulatory mechanisms, and tissue distributions. This diversity enables precise spatial-temporal control over numerous biological pathways—and makes them important drug targets across many therapeutic areas, including cardiovascular disease, inflammation, and neurological disorders.
Selective inhibition of phosphodiesterase isoforms, leading to increased intracellular levels of cAMP and/or cGMP, depending on the isoform targeted.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase Enzyme Family (None).